Skip to main content
. 2024 Oct 17;25(20):11192. doi: 10.3390/ijms252011192

Table 2.

Genotype and allele frequencies of ASTN1, EBF1, EEFSEC, MAST1, and TNF-α gene polymorphisms among cases and controls.

Cases
(N = 292)
Controls
(N = 281)
χ2 * p p adj **
ASTN1 rs146756455 G/C
genotype GG 277 (95.85) 264 (95.31) 1.23 0.542 3.276
GC 11 (3.81) 13 (4.69)
AC 1 (0.34) 0
allele G 564 (97.58) 538 (97.11) 0.24 0.626 2.136
A 14 (2.42) 16 (2.89)
EBF1 SNP rs2963463 T/C
genotype TT 25 (8.68) 17 (6.09) 10.47 0.005 0.030
TC 156 (54.1) 121 (43.37)
CC 107 (37.22) 141 (50.54)
allele T 182 (31.60) 155 (27.78) 1.98 0.160 0.960
C 394 (68.40) 403 (72.22)
EBF1 rs2946169 C/T
genotype CC 165 (57.10) 180 (64.52) 4.78 0.092 0.552
CT 103 (35.64) 88 (31.54)
TT 21 (7.26) 11 (3.94)
allele C 433 (74.91) 450 (80.65) 5.38 0.020 0.120
T 145 (25.09) 108 (19.35)
TNF-α rs1800629 G/A
genotype GG 208 (71.23) 213 (75.80) 7.68 0.104 0.624
GA 70 (23.97) 59 (21.00)
AA 14 (4.80) 9 (3.20)
allele G 486 (83.22) 485 (86.47) 2.10 0.148 0.888
A 98 (16.78) 77 (13.70)

Bold denotes statistical significance. * Pearson chi-square test. ** Bonferroni correction. Genotype data were available for ASTN1 cases 289/292 (99.0%) and 277/281 (98.6%) controls; EBF1 cases 288/292 (98.6%) and 279/281 (93.3%) controls; and TNF-α cases 292/292 (100.0%) and 281/281 (100.0%) controls.

HHS Vulnerability Disclosure